CANCER THERAPY: CLINICAL

4449 Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

4459 p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses
Nicola R. Hardwick, Mary Carroll, Teodora Kalcheva, Dajun Qian, Dean Lim, Lucille Leong, Pei guo Chu, Joseph Kim, Joseph Chao, Marwan Fakih, Yun Yen, Jonathan Espenschied, Joshua D.I. Ellenhorn, Don J. Diamond, and Vincent Chung

PERSONALIZED MEDICINE AND IMAGING

4471 Phase I Safety and Pharmacodynamics of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients
Jacques Medioni, Gael Deplanque, Jean-Marc Ferrero, Tristan Maurina, Jean-Alain Kermarrec, Eric Raymond, Jorge Alfonso, Gerald Mariani, Pascal Houillier, Sarah Mackenzie, Stephanie Renaux, Jean-François Dufour-Lamartine, Reza Elaïdi, Celine Lerest, and Stephanie Oudard

4488 Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
See related commentary, p. 4422
CANCER THERAPY: PRECLINICAL

4559 Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Lapatinib Unresponsiveness in HER2-Positive Gastric Cancer
Zhe Zhang, Jinping Wang, Dongmei Ji, Chencheng Wang, Ruijiao Liu, Zheng Wu, Lian Liu, Dan Zhu, Jinjia Chang, Ruixuan Geng, Lei Xiong, Qiangyi Fang, and Jun Li

4574 SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies
Jutta Deckert, Marie-Cécile Wetzel, Laura M. Bartle, Anna Skaletskaya, Victor S. Golubchek, François Vallée, Qing Zhou-Liu, Paul Ferrari, Stéphanie Pouzieux, Charlotte Lahoute, Charles Dumontet, Adriana Plesa, Marielle Chiron, Pascale Lejeune, Thomas Chittenden, Peter U. Park, and Véronique Blanc

BIOLOGY OF HUMAN TUMORS

4598 Large-Scale Characterization of DNA Methylation Changes in Human Gastric Carcinomas with and without Metastasis
Zhaojun Liu, Jun Zhang, Yanhong Gao, Lirong Pei, Jing Zhou, Liankun Gu, Lianhai Zhang, Budong Zhu, Naoko Hattori, Jiafu Ji, Yasuhito Yuasa, Woooho Kim, Toshikazu Ushijima, Huidong Shi, and Dajun Deng

4613 Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/IFCT-1002
Sébastien Couraud, Felipe Vaca-Paniagua, Stéphanie Villar, Javier Oliver, Tibor Schuster, Hélène Blanche, Nicolas Giraud, Jean Trédaniel, Laurent Guilleminault, Rady Gervais, Nathalie Prim, Michel Vincent, Jacques Margery, Sébastien Larivière, Pascal Foucher, Bernard Duvert, Maxime Vallée, Florence Le Calvez-Kelm, James McKay, Pascale Missy, Franck Morin, Gérard Zalcman, Magali Olivier, and Pierre-Jean Souquet for the BioCAST/IFCT-1002 investigators
Expression of Androgen and Estrogen Signaling Components and Stem Cell Markers to Predict Cancer Progression and Cancer-Specific Survival in Patients with Metastatic Prostate Cancer

Tetsuya Fujimura, Satoru Takahashi, Tomohiko Urano, Kenichi Takayama, Toru Sugihara, Daisuke Obinata, Yuta Yamada, Jimpiei Kumagai, Haruki Kume, Yasuyoshi Ouchi, Satoshi Inoue, and Yukio Homma

miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer

Sajni Josson, Murali Gururajan, Peizhen Hu, Chen Shao, Gina Chia-Yi Chu, Haiyen E. Zhai, Chunyan Liu, Kaiqin Lao, Chi-Lun Lu, Yi-Tsung Lu, Jake Lichterman, Srinivas Nandana, Quanlin Li, Andre Rogatko, Dror Berel, Edwin M. Posadas, Ladan Fazli, Dhruv Sareen, and Leland W.K. Chung

Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer

Miguel A. Molina-Vila, Jordi Bertran-Alamillo, Amaya Gasco, Clara Mayo-de-las-Casas, Maria Sanchez-Ronco, Laia Pujantell-Pastor, Laura Bonanno, Adolfo G. Favaretto, Andres F. Cordona, Alain Vergnenegre, Margarita Majem, Bartomeu Massuti, Teresa Morán, Enric Carcereny, Santiago Viteri, and Rafael Rosell

See related commentary, p. 4419

An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non–Small Cell Lung Cancer

Ren-Tao Wang, Meng Xu, Cheng-Xiong Xu, Zhi-Gang Song, and Hua Jin

TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome

Tiantian Sun, Wan Du, Hua Xiong, Yanan Yu, Yurong Weng, Linlin Ren, Huijun Zhao, Yingchao Wang, Yingxuan Chen, Jie Xu, Yongbing Xiang, Wexin Qin, WeiNao Cao, Weiping Zou, Haoyan Chen, Jie Hong, and Jing-Yuan Fang

To “Grow” or “Go”: TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN

Daniel J. Shiawasaki, Chunbo Shao, Anke Bill, Jean Kim, Dong Xiao, Carol A. Bertrand, Raja S. Seethala, Daisuke Sano, Jeffery N. Myers, Patrick Ha, Jennifer Grandis, L. Alex Gaither, Manojkumar A. Puthenveedu, and Umamaheswar Duvvuri

Decreased Expression of miR216a Contributes to Non–Small-Cell Lung Cancer Progression

Hong Zhang, Wei Hou, Hua-Li Wang, Hai-Jing Liu, Xin-Ying Jia, Xing-Zheng Zheng, Yong-Xin Zou, Xin Li, Lin Hou, Michael A. McNutt, and Bo Zhang

GSK-3β–Regulated N-Acetyltransferase 10 Is Involved in Colorectal Cancer Invasion

Tiantian Sun, Wan Du, Hua Xiong, Yanan Yu, Yurong Weng, Linlin Ren, Huijun Zhao, Yingchao Wang, Yingxuan Chen, Jie Xu, Yongbing Xiang, Wexin Qin, WeiNao Cao, Weiping Zou, Haoyan Chen, Jie Hong, and Jing-Yuan Fang

Decreased Expression of miR216a Contributes to Non–Small-Cell Lung Cancer Progression

Ren-Tao Wang, Meng Xu, Cheng-Xiong Xu, Zhi-Gang Song, and Hua Jin

GSK-3β–Regulated N-Acetyltransferase 10 Is Involved in Colorectal Cancer Invasion

Hong Zhang, Wei Hou, Hua-Li Wang, Hai-Jing Liu, Xin-Ying Jia, Xing-Zheng Zheng, Yong-Xin Zou, Xin Li, Lin Hou, Michael A. McNutt, and Bo Zhang
ABOUT THE COVER

The cover shows the crystal structure of the SAR650984-Fab in complex with human CD38 resolved at 1.53 Å resolution. A close-up view of the epitope highlights the interface between human CD38 and SAR650984-Fab, which involves mainly antibody heavy chain CDR loop H3 (yellow) and light chain CDR loops L1, L2 and L3 (green). For details, see the article by Deckert and colleagues on page 4574 of this issue.